(Date:11/19/2009)...ov. 19 /PRNewswire/ - Aegera Therapeutics Inc. ann...randomized Phase 2B study of AEG35156, a targeted ... multiple oncology indications. ,, The study, e... the X-Linked Inhibitor of Apoptosis (XIAP) Antise...ytarabine and Idarubicin in AML Following Failure ...
(Date:11/18/2009)...., Nov. 18 Marrone Bio Innovations... commercialization of effective and environmentall...that it has been named an IC20 company by the Inve...st national angel investing group. ,, Companies... rewarding results for all stakeholders, including...
(Date:11/18/2009)...Calif., Nov. 18 Sangamo ... that data from the University of Pennsylvania inv...o,s zinc finger nuclease (ZFN) based product, SB-7...ely disclosed on the internet. ,, Data were pre...nnsylvania School of Medicine from a single subjec...
(Date:11/18/2009)... ON, Nov. 18 /PRNewswire-FirstCall/ - YM BioScienc...es product development company that identifies and...related products at various stages of development,...motuzumab were presented today in a poster at the ...herapeutics conference in Boston, Massachusetts. T...
Breaking Biology Technology:Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML) 2Marrone Bio Innovations Named an IC20 Company 2Sangamo BioSciences Provides Update on Phase 1 Safety Trial of SB-728-T for HIV/AIDS 2YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB RESULTS IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER MODEL PRESENTED AT AACR-NCI-EORTC MEETING 2YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB RESULTS IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER MODEL PRESENTED AT AACR-NCI-EORTC MEETING 3...RCELONA, February 26 Prous Institute for Biomedic...g discovery on its newly,designed website ( http:/...oject with basic research support and broad diseas...nder the broad-based Epistemic Drug,Discovery(R) p...e, Dr. J.R. Prous, explained that "We,are committe...
...LO, Norway, February 26 ScreenCancer AS, a Norweg...ervices to employers, insurance,companies and indi...ure(R),FIT(TM) take-at-home colorectal cancer scre...m. The company,s two-year distribution agreement w...s Incorporated (NYSE: DGX ), the world,leader in...
...ra(R) SoloSTAR(R) is a Convenient Insulin Delivery...cemic Control , , BRIDGEWATER, N.J., Feb. 26 San... Drug Administration (FDA) approved Apidra(R) Solo...), a prefilled disposable pen containing rapid-act...o improve glycemic control in adults and children ...
Other Biology Technology:Prous Institute Presents Innovative Approach to Drug Discovery 2ScreenCancer Adds InSure(R) FIT(TM) Colorectal Cancer Screening Test to European Cancer Screening Program 2ScreenCancer Adds InSure(R) FIT(TM) Colorectal Cancer Screening Test to European Cancer Screening Program 3FDA Approves Apidra(R) SoloSTAR(R) - a Prefilled Disposable Insulin Pen 2FDA Approves Apidra(R) SoloSTAR(R) - a Prefilled Disposable Insulin Pen 3FDA Approves Apidra(R) SoloSTAR(R) - a Prefilled Disposable Insulin Pen 4FDA Approves Apidra(R) SoloSTAR(R) - a Prefilled Disposable Insulin Pen 5FDA Approves Apidra(R) SoloSTAR(R) - a Prefilled Disposable Insulin Pen 6FDA Approves Apidra(R) SoloSTAR(R) - a Prefilled Disposable Insulin Pen 71-D PAGE Cleavable ICAT Reagent Applications Development Kit for Targeted Protein ID and Quantitation (monoplex Version) from Applied Biosystems
Propidium Iodide (1 mg/ml). from BioVision
Custom Production Service - Purification from AbD Serotec
Single-stranded carrier DNA, 3 x 1 ml from Dualsystems Biotech AG
Biology Products: